**Exhibit 10.3**

 

**OPTIMER BIOTECHNOLOGY, INC.**

** **

**FINANCING AGREEMENT**

** **

**THIS FINANCING AGREEMENT**(this ***“Agreement”***) is made and entered into asof October 30, 2009, by and among **OPTIMER BIOTECHNOLOGY,INC.**, a Taiwan corporation(the ***“Company”***),and each of those persons and entities, severally and not jointly, whose namesare set forth on the Schedule of Purchasers attached hereto as **EXHIBIT A** (which persons and entitiesare hereinafter collectively referred to as ***“Purchasers”*** and each individually as a ***“Purchaser”***).

 

**RECITALS**

** **

**WHEREAS**, the Company has authorized the sale and issuance toPurchasers of up to 66,000,000 shares of its Common Stock (the ***“Shares”***) to be soldby the Company pursuant to the terms and conditions of this Agreement (the ***“Common Stock Sale”***);

 

**WHEREAS**, Purchasers desire to purchase the Shares on theterms and conditions set forth herein;

 

**WHEREAS,** Optimer Pharmaceuticals, Inc. (***“Optimer”***) and the other Purchasersare concurrently entering into a Stock Purchase Agreement whereby Optimer willsell to the other Purchasers certain shares of the Company currently held byOptimer and the other Purchasers’ commitments under this Agreement are amaterial inducement for Optimer to sell such shares; and

 

**WHEREAS**, the Company desires to issue and sell the Shares toPurchasers on the terms and conditions set forth herein.

 

**AGREEMENT**

 

**NOW, THEREFORE**, in consideration of the foregoing recitals and themutual promises, representations, warranties, and covenants hereinafter setforth and for other good and valuable consideration, the receipt andsufficiency of which are hereby acknowledged, the parties hereto agree asfollows:

 

**1.****                                     ****AGREEMENT TO SELL AND PURCHASE.**

 

**1.1         ****Authorization of Shares**.  The Companyhas authorized the sale and issuance to Purchasers of the Shares.  The Shares have the rights, preferences,privileges and restrictions set forth in the Company’s charter documents ineffect on the date hereof.

 

**1.2         ****Sale and Purchase**.  Subject to the terms andconditions hereof, at the First Closing or the Second Closing, as applicable(each as hereinafter defined, and any such closing referred to herein as a ***“Closing”*** and the date on which suchClosing takes effect, a ***“Closing Date”***)the Company hereby agrees to issue and sell to each Purchaser, and eachPurchaser agrees to purchase from the Company, severally and not jointly, thenumber of Shares set forth opposite such Purchaser’s name on the Schedule ofPurchasers attached hereto as **EXHIBIT A**

 

1

----

 

under the heading “FirstClosing Shares” and “Second Closing Shares”, as applicable, at a purchase priceof 10 New Taiwan Dollars (NT) per share.

 

**2.****                                     ****CLOSING, DELIVERY AND PAYMENT.**

 

**2.1         ****First Closing. **The first closing of the sale andpurchase of the Shares under this Agreement (the ***“First Closing”***) shall take place at5:00 p.m. Pacific Time on the date hereof, at the offices of CooleyGodward Kronish LLP, 4401 Eastgate Mall, San Diego, CA, 92121 or at such othertime or place as the Company and Purchasers may mutually agree (such date ishereinafter referred to as the ***“First Closing Date”***). On the First Closing Date, subject to the terms and conditions hereof,the Company will deliver to each Purchaser a certificate representing thenumber of Shares to be purchased at the First Closing by such Purchaser, as setforth on the Schedule of Purchasers, against payment of the purchase pricetherefor by check or wire transfer made payable to the order of the Company,cancellation or conversion of indebtedness or any combination of theforegoing.  In the event that payment bya Purchaser is made, in whole or in part, by cancellation or conversion ofindebtedness, then such Purchaser shall surrender to the Company forcancellation or conversion at the First Closing any evidence of suchindebtedness or shall execute an instrument of cancellation or conversion inform and substance acceptable to the Company.

 

**2.2         ****Second Closing. **If at any time prior to December 31, 2010, theCompany’s Board of Directors determines in good faith that the Company hasachieved each of the milestones set forth on **EXHIBIT B**attached hereto, the Company shall provide written notice of such determinationto the Purchasers (the ***“SecondClosing Notice”***), which notice shall not be delivered prior to June 30,2010.  The Second Closing Notice shallalso set forth a date, which shall be no sooner than 5 businessdays and no later than 15 business days following the date of the SecondClosing Notice, onwhich the second closing of the sale and purchase of the Shares under thisAgreement (the ***“Second Closing”***) shall take place.  Following delivery of the Second ClosingNotice, the Second Closing shalltake place at 5:00 p.m. Pacific Time at the offices of Cooley GodwardKronish LLP, 4401 Eastgate Mall, San Diego, CA, 92121 on the date set forth inthe Second Closing Notice, or at such other time as the Company and thePurchasers holding a majority of the Shares then issued hereunder (the ***“Majority Purchasers”***) may mutuallyagree (the ***“Second Closing Date”***). On the Second Closing Date, subject to the terms and conditions hereof,the Company will deliver to each Purchaser a certificate representing thenumber of Shares to be purchased at the Second Closing by such Purchaser, asset forth on the Schedule of Purchasers**,** againstpayment of the purchase price therefor by check or wire transfer made payableto the order of the Company, cancellation or conversion of indebtedness or anycombination of the foregoing.  In theevent that payment by a Purchaser is made, in whole or in part, by cancellationor conversion of indebtedness, then such Purchaser shall surrender to theCompany for cancellation or conversion at the Second Closing any evidence ofsuch indebtedness or shall execute an instrument of cancellation or conversionin form and substance acceptable to the Company.

 

2

----

 

**3.****                                     ****REPRESENTATIONS AND WARRANTIES OFTHE COMPANY.**

 

Except as set forth on aSchedule of Exceptions delivered by the Company to Purchasers at an applicableClosing, the Company hereby represents and warrants to each Purchaser as ofeach Closing Date as set forth below.

 

**3.1         ****Corporate Power.** The Company has all necessary corporate power to execute and deliverthis Agreement and to perform all its obligations hereunder.  Upon its execution and delivery, thisAgreement will be a valid and binding obligation of the Company, enforceable inaccordance with its terms.

 

**3.2         ****Capitalization.** Immediately prior to the First Closing, there are 34,000,000 shares ofthe Company’s common stock outstanding.

 

**3.3         ****No Subsidiaries.** The Company does not own more than 50% of the outstanding capital stock(or other similar equity interests) of any corporation or other entity thatowns any material assets.

 

**3.4         ****Litigation.** There is no material lawsuit or other material legal proceeding that ispending against the Company before any court or other tribunal and that (a) islikely to result in a final judgment adverse to the Company, and (b) islikely to have a material adverse effect on the Company’s business.

 

**3.5         ****Authorization.** As of the First Closing Date, the execution, delivery and performance ofthis Agreement on behalf of the Company will have been duly authorized by allnecessary action on the part of the Company and its board of directors.

 

**4.****                                     ****REPRESENTATIONS AND WARRANTIES OFPURCHASERS.**

 

Each Purchaser hereby represents and warrants to theCompany, severally and not jointly, on each Closing Date as follows (providedthat such representations and warranties do not lessen or obviate therepresentations and warranties of the Company set forth in this Agreement):

 

**4.1         ****Power.** Purchaser has all necessary power (corporate or otherwise) to executeand deliver this Agreement and to perform all its obligations hereunder.  Upon its execution and delivery, thisAgreement will be a valid and binding obligation of Purchaser, enforceable inaccordance with its terms. Purchaser’s financial resources are sufficient toenable it to purchase the Shares as provided herein.

 

**4.2         ****Access.** Purchaser has been given full access to the assets, books, records,contracts and employees of the Company, and has been given the opportunity tomeet with officers and other representatives of the Company for the purpose ofinvestigating and obtaining information regarding the Company’s business,operations and legal affairs.

 

**4.3         ****Authorization.** The execution, delivery and performance of this Agreement on behalf ofPurchaser have been duly authorized by all necessary action on the part ofPurchaser and, if applicable, its board of directors.

 

3

----

 

**4.4         ****Brokers.** Purchaser has not retained any broker or finder in connection with anyof the transactions contemplated by this Agreement, and Purchaser has notincurred or agreed to pay, or taken any other action that would entitle anyperson or entity to receive, any brokerage fee, finder’s fee or other similarfee or commission with respect to any of the transactions contemplated by thisAgreement.

 

**4.5         ****Acquisition.** Purchaser is acquiring its portion of the Shares for its own account andfor investment, and not with a view to, or for sale in connection with, anydistribution of the Shares.

 

**5.****                                     ****CONDITIONS TO CLOSING**.

 

**5.1         ****Conditions to Purchasers’Obligations at each Closing**.  EachPurchaser’s obligations to purchase and otherwise consummate the transactionsthat are to be consummated at each Closing are subject to the satisfaction ofthe following conditions (any of which may be waived by such Purchaser in wholeor in part)

 

**(a)          ****Accuracy of Representations andWarranties.**  The representations and warranties of theCompany set forth in Section 3 shall be accurate in all material respectsas of each Closing Date, except to the extent that any of such representationsand warranties refer specifically to a date other than the applicable ClosingDate, and except as set forth on a Schedule of Exceptions.

 

**(b)          ****Performance.** The Company shall have performed, in all material respects, allobligations required by this Agreement to be performed by the Company on orbefore the applicable Closing Date.

 

**(c)          ****No Injunction.** There shall not be in effect at the applicable Closing Date anyinjunction or other binding order of any court or other tribunal havingjurisdiction over Purchaser that prohibits the purchase of the Shares byPurchaser.

 

**(d)          ****License Agreement.** Optimer and the Company shall have executed and delivered that certainIntellectual Property Assignment and License Agreement between such parties, ofeven date herewith (the ***“License Agreement”***).

 

**(e)          ****Stock Purchase Agreement.** Optimer and the other Purchasers shall have executed and delivered thatcertain Stock Purchase Agreement between such parties, of even date herewith(the ***“Stock Purchase Agreement”***).

 

**(f)           ****Assignment Agreements.**  Optimer,the Company and The Scripps Research Institute shall have executed anddelivered the Scripps Assignment (as defined in the License Agreement) andOptimer, the Company and the Memorial Sloan-Kettering Cancer Center shall have executed anddelivered the MSKCC Assignment (as defined in the License Agreement).

 

**5.2         ****Conditions to Obligations of theCompany**.  The Company’s obligation to issue and sellthe Shares at each Closing is subject to the satisfaction, on or prior to theapplicable Closing, of the following conditions:

 

4

----

 

**(a)          ****Accuracy of Representations andWarranties.**  The representations and warranties of eachPurchaser set forth in Section 4 shall be accurate in all materialrespects as of the applicable Closing Date.

 

**(b)          ****Performance.** Each Purchaser shall have performed, in all material respects, allobligations required by this Agreement to be performed by such Purchaser on orbefore the applicable Closing Date.

 

**(c)          ****No Injunction.** There shall not be in effect at the applicable Closing Date anyinjunction or other binding order of any court or other tribunal havingjurisdiction over the Company that prohibits the sale of any of the Shares toPurchasers.

 

**(d)          ****License Agreement.** Optimer shall have executed and delivered the LicenseAgreement.

 

**(e)          ****Stock Purchase Agreement.** Optimer and the other Purchasers shall haveexecuted and delivered the Stock Purchase Agreement.

 

**(f)           ****Assignment Agreements.** The Scripps Research Institute shall have executed and delivered theScripps Assignment and the Memorial Sloan-Kettering Cancer Center shall have executed anddelivered the MSKCC Assignment.

 

**6.****                                     ****MISCELLANEOUS**.

 

**6.1         ****Governing Law; Arbitration**. This Agreement shall be governed by and construed under the laws of theState of California in all respects as such laws are applied to agreementsamong California residents entered into and performed entirely withinCalifornia, without giving effect to conflict of law principles thereof.  The parties agree that any action brought byeither party under or in relation to this Agreement, including withoutlimitation to interpret or enforce any provision of this Agreement, shall bebrought in, and each party agrees to and does hereby submit to the jurisdictionand venue of, any state or federal court located in the County of San Diego,California.  The foregoingnotwithstanding, any dispute between the parties that cannot be resolvedthrough good faith discussions shall be submitted to binding arbitration.  Any arbitration pursuant to this Section 6.1shall be conducted in San Diego, California (or such other location upon whichthe parties may mutually agree) before a single arbitrator with JudicialArbitration and Mediation Services, Inc. (***“JAMS”***)or its successor, pursuant to the applicable JAMS rules and proceduresthen in effect.  The arbitrator shallhave the authority to compel adequate discovery for the resolution of thedispute, including, but not limited to, access to essential documents andwitnesses.  The arbitrator shall issue awritten arbitration decision setting forth his or her essential findings andconclusions and a statement of the award, which decision shall be final andbinding on the parties.

 

**6.2         ****Survival**. The representations, warranties, covenants and agreements made hereinshall survive the closing of the transactions contemplated hereby.  All statements as to factual matterscontained in any certificate or other instrument delivered by or on behalf ofthe Company pursuant hereto in connection with the transactions contemplatedhereby shall be deemed to be representations and warranties by the Companyhereunder solely as of the date of such certificate or instrument.  The representations, warranties, covenants andobligations of the 

 

5

----

 

Company, and the rightsand remedies that may be exercised by the Purchasers, shall not be limited orotherwise affected by or as a result of any information furnished to, or anyinvestigation made by or knowledge of, any of the Purchasers or any of theirrepresentatives.

 

**6.3         ****Successors and Assigns**. Except as otherwise expressly provided herein, the provisions hereofshall inure to the benefit of, and be binding upon the parties hereto and theirrespective successors, assigns, heirs, executors and administrators and shallinure to the benefit of and be enforceable by each person who shall be a holderof the Shares from time to time; *provided, however*,that prior to the receipt by the Company of adequate written notice of thetransfer of any Shares specifying the full name and address of the transferee,the Company may deem and treat the person listed as the holder of such Sharesin its records as the absolute owner and holder of such Shares for allpurposes.

 

**6.4         ****Entire Agreement**. This Agreement, the exhibits hereto and the exhibits thereto set forththe entire understanding of the parties hereto, and supersede all otheragreements and understandings between the parties hereto, relating to thesubject matter hereof and thereof.

 

**6.5         ****Severability**. In the event one or more of the provisions of this Agreement should, forany reason, be held to be invalid, illegal or unenforceable in any respect,such invalidity, illegality or unenforceability shall not affect any otherprovisions of this Agreement, and this Agreement shall be construed as if suchinvalid, illegal or unenforceable provision had never been contained herein.

 

**6.6         ****Amendment and Waiver**. This Agreement may be amended ormodified, and the obligations of the Company and the rights of the holders ofthe Shares under this Agreement may be waived, only upon the written consent ofthe Company and the Majority Purchasers.

 

**6.7         ****Delays or Omissions**. It is agreed that no delay or omission to exercise any right, power orremedy accruing to any party, upon any breach, default or noncompliance byanother party under this Agreement shall impair any such right, power orremedy, nor shall it be construed to be a waiver of any such breach, default ornoncompliance, or any acquiescence therein, or of or in any similar breach,default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent or approval of anykind or character on any party’s part of any breach, default or noncomplianceunder this Agreement or any waiver on such party’s part of any provisions orconditions of this Agreement must be in writing and shall be effective only tothe extent specifically set forth in such writing.  All remedies, either under this Agreement, bylaw, or otherwise afforded to any party, shall be cumulative and notalternative.

 

**6.8         ****Waiver of Conflicts**. Each party to this Agreement acknowledges that Cooley Godward Kronish LLP(***“Cooley”***),outside general counsel to Optimer, has in the past performed and is or may nowor in the future represent the Company in matters unrelated to the transactionscontemplated by this Agreement (the ***“Financing”***), including representation of theCompany in matters of a similar nature to the Financing.  The applicable rules of professionalconduct require that Cooley inform the parties hereunder of this representationand obtain their consent.  Cooley hasserved as outside general counsel to Optimer and has negotiated the terms ofthe Financing solely on behalf of Optimer. Optimer, the Company and each Purchaser other than Optimer (***“Other Purchasers”***) hereby (a) acknowledgethat they have had an opportunity to ask for and

 

6

----

 

have obtained informationrelevant to such representation, including disclosure of the reasonablyforeseeable adverse consequences of such representation; (b) acknowledgethat with respect to the Financing, Cooley has represented solely Optimer, andnot the Company or any Other Purchasers or any stockholder, director oremployee of Optimer, the Company or any Other Purchasers; and (c) givesits informed consent to Cooley’s representation of Optimer in the Financing.

 

**6.9         ****Notices**. All notices required or permitted hereunder shall be in writing andshall be deemed effectively given: (a) upon personal delivery to the partyto be notified, (b) when sent by confirmed electronic mail, telex orfacsimile if sent during normal business hours of the recipient, if not, thenon the next business day, (c) five (5) days after having been sent byregistered or certified mail, return receipt requested, postage prepaid, or (d) one(1) day after deposit with a nationally recognized overnight courier,specifying next day delivery, with written verification of receipt.  All communications shall be sent to theCompany at the address as set forth on the signature page hereof and toany Purchaser at the address set forth on **EXHIBIT A**attached hereto or at such other address or electronic mail address as theCompany or a Purchaser may designate by ten (10) days advance writtennotice to the other parties hereto.

 

**6.10       ****Attorneys’ Fees**. In the event that any suit or action is instituted under or in relationto this Agreement, including without limitation to enforce any provision inthis Agreement, the prevailing party in such dispute shall be entitled torecover from the losing party all fees, costs and expenses of enforcing anyright of such prevailing party under or with respect to this Agreement,including without limitation, such reasonable fees and expenses of attorneysand accountants, which shall include, without limitation, all fees, costs andexpenses of appeals.

 

**6.11       ****Titles and Subtitles**. The titles of the sections and subsections of this Agreement are forconvenience of reference only and are not to be considered in construing thisAgreement.

 

**6.12       ****Counterparts; Facsimile**. This Agreement may be executed in any number of counterparts, each ofwhich shall be an original, but all of which together shall constitute oneinstrument.  Facsimile signatures shallhave the same force and effect as originals.

 

**6.13       ****Exculpation Among Purchasers**. Each Purchaser acknowledges that it is not relying upon any person,firm, or corporation, other than the Company and its officers and directors, inmaking its investment or decision to invest in the Company.  Each Purchaser agrees that no Purchaser northe respective controlling persons, officers, directors, partners, agents, oremployees of any Purchaser shall be liable to any other Purchaser for anyaction heretofore taken or omitted to be taken by any of them in connectionwith the purchase of the Shares.

 

**6.14       ****Pronouns**. All pronouns contained herein, and any variations thereof, shall be deemedto refer to the masculine, feminine or neutral, singular or plural, as to theidentity of the parties hereto may require.

 

[SIGNATURE PAGE FOLLOWS]

 

7

----

 

**IN WITNESS WHEREOF,**the parties hereto have executed this **FINANCING****AGREEMENT** as ofthe date set forth in the first paragraph hereof.

 
| **COMPANY:**                     |                                   |
|----------------------------------|----------------------------------------|
| ** **                       |                                   |
| **OPTIMER  BIOTECHNOLOGY, INC.** |                                   |
| ** **                       |                                   |
| ** **                       |                                   |
| By:                              | /s/ Youe-Kong  Shue, Ph.D.        |   |
| Name:                            | Youe-Kong Shue, Ph.D.                  |   |
| Title:                           | President & CEO               |   |
| Address:                         | Room W1907, 19F, 3 Yuan Qu Street |   |
|                             | Nankang Software Park                  |   |
|                             | Taipei 115, Taiwan                     |   |
|                                  |                                        |  |  |

 

[SIGNATURE PAGE TOFINANCING AGREEMENT]

 

----

 
|       | **PURCHASERS:**                   |
|------------|-----------------------------------|
| ** ** | ** **                        |
|       | **OPTIMER PHARMACEUTICALS, INC.** |
| ** ** | ** **                        |
| ** ** | ** **                        |
|       | By:                               | /s/ Michael N. Chang |
|       | Name:                             | Michael N. Chang |
|       | Title:                            | CEO |

 
| **NAME AND  ADDRESS**                                                                                             | ** ** | **FIRST CLOSING  SHARES** | ** ** | **FIRST CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** | **SECOND  CLOSING SHARES** | ** ** | **SECOND CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** |
|-------------------------------------------------------------------------------------------------------------------|------------|---------------------------|------------|----------------------------------------------|------------|----------------------------|------------|-----------------------------------------------|------------|
| ** **                                                                                                        | ** ** | ** **                | ** ** | ** **                                   | ** ** | ** **                 | ** ** | ** **                                    | ** ** |
| **OPTIMER PHARMACEUTICALS, INC.**10110 Sorrento Valley Rd.,  Suite C  San Diego, CA 92121  Attn: John Prunty |       | 11,880,000                |       | NT $118,800,000                              |       | 27,720,000                 |       | NT $277,200,000                               |       |

 

[SIGNATURE PAGE TOFINANCING AGREEMENT]

 

----

 
|       | **PURCHASERS:**                    |
|------------|------------------------------------|
| ** ** | ** **                         |
|       | **HUEI HONG INVESTMENT CO., LTD.** |
| ** ** | ** **                         |
| ** ** | ** **                         |
|       | By:                                | /s/ Chuan-tai Cheng |
|       | Name:                              | Chuan-tai Cheng |
|       | Title:                             |   |

 
| **NAME AND  ADDRESS**                                                                                                | ** ** | **FIRST CLOSING  SHARES** | ** ** | **FIRST CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** | **SECOND  CLOSING SHARES** | ** ** | **SECOND CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** |
|----------------------------------------------------------------------------------------------------------------------|------------|---------------------------|------------|----------------------------------------------|------------|----------------------------|------------|-----------------------------------------------|------------|
| ** **                                                                                                           | ** ** | ** **                | ** ** | ** **                                   | ** ** | ** **                 | ** ** | ** **                                    | ** ** |
| **HUEI HONG  INVESTMENT CO., LTD.**11F, No. 308, Section 2, Bade  RoadTaipei 10492, TaiwanAttn: Frank Chen |       | 1,188,000                 |       | NT $11,880,000                               |       | 2,772,000                  |       | NT $27,720,000                                |       |

 

[SIGNATURE PAGE TOFINANCING AGREEMENT]

 

----

 
|       | **PURCHASERS:**                                                                                      |
|------------|------------------------------------------------------------------------------------------------------|
| ** ** | ** **                                                                                           |
|       | **UNIMED****I****NVESTMENT INC.**                                                                    |
| ** ** | **合一生技投資股份有限公司** |
| ** ** | ** **                                                                                           |
| ** ** | ** **                                                                                           |
|       | By:                                                                                                  | /s/ William Lu |
|       | Name:                                                                                                | William Lu |
|       | Title:                                                                                               | Chairman |

 
| **NAME AND  ADDRESS**                                                                                                                                                                                                    | ** ** | **FIRST CLOSING  SHARES** | ** ** | **FIRST CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** | **SECOND  CLOSING SHARES** | ** ** | **SECOND CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------|------------|----------------------------------------------|------------|----------------------------|------------|-----------------------------------------------|------------|
| ** **                                                                                                                                                                                                               | ** ** | ** **                | ** ** | ** **                                   | ** ** | ** **                 | ** ** | ** **                                    | ** ** |
| **UNIMED****I****NVESTMENT  INC.**

**合一生技投資股份有限公司**3F, No. 308, Section 2, Bade  RoadTaipei 10492, TaiwanAttn: Howard Lee |       | 1,584,000                 |       | NT $15,840,000                               |       | 3,696,000                  |       | NT $36,960,000                                |       |

 

[SIGNATURE PAGE TO FINANCINGAGREEMENT]

 

----

 
|       | **PURCHASERS:**                                                                                      |
|------------|------------------------------------------------------------------------------------------------------|
| ** ** | ** **                                                                                           |
|       | **E.SUN****V****ENTURE****C****APITAL****C****O.,****L****TD.**                                      |
| ** ** | **玉山創業投資股份有限公司** |
| ** ** | ** **                                                                                           |
| ** ** | ** **                                                                                           |
|       | By:                                                                                                  | /s/ Nanchou Huang |
|       | Name:                                                                                                | Nanchou Huang |
|       | Title:                                                                                               | CEO |

 
| **NAME AND  ADDRESS**                                                                                                                                                                                                                                  | ** ** | **FIRST CLOSING  SHARES** | ** ** | **FIRST CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** | **SECOND  CLOSING SHARES** | ** ** | **SECOND CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------|------------|----------------------------------------------|------------|----------------------------|------------|-----------------------------------------------|------------|
| ** **                                                                                                                                                                                                                                             | ** ** | ** **                | ** ** | ** **                                   | ** ** | ** **                 | ** ** | ** **                                    | ** ** |
| **E.SUN****V****ENTURE****C****APITAL****C****O.,****L****TD.**

**玉山創業投資股份有限公司**14F, No. 117, Section  3,Minsheng E. RoadTaipei 10546, TaiwanAttn: Mike Tsai |       | 950,400                   |       | NT $9,504,000                                |       | 2,217,600                  |       | NT $22,176,000                                |       |

 

[SIGNATURE PAGE TOFINANCING AGREEMENT]

 

----

 
|       | **PURCHASERS:**                     |
|------------|-------------------------------------|
| ** ** | ** **                          |
|       | **H****UNG****-M****EI****Y****EH** |
| ** ** | **葉鴻美**        |
| ** ** | ** **                          |
| ** ** | ** **                          |
|       | By:                                 | /s/ Hung-Mei Yeh |
|       | Name:                               | Hung-Mei Yeh |
|       | Title:                              |   |

 
| **NAME AND  ADDRESS**                                                                                                                          | ** ** | **FIRST CLOSING  SHARES** | ** ** | **FIRST CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** | **SECOND  CLOSING SHARES** | ** ** | **SECOND CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** |
|------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------|------------|----------------------------------------------|------------|----------------------------|------------|-----------------------------------------------|------------|
| ** **                                                                                                                                     | ** ** | ** **                | ** ** | ** **                                   | ** ** | ** **                 | ** ** | ** **                                    | ** ** |
| **H****UNG****-M****EI****Y****EH**

葉鴻美14F, No. 117, Section  3,Minsheng E. RoadTaipei 10546, TaiwanAttn: Mike Tsai |       | 237,600                   |       | NT $2,376,000                                |       | 554,400                    |       | NT $5,544,000                                 |       |

 

[SIGNATURE PAGE TOFINANCING AGREEMENT]

 

----

 
|       | **PURCHASERS:**                                                                                      |
|------------|------------------------------------------------------------------------------------------------------|
| ** ** | ** **                                                                                           |
|       | **S****INOPAC****V****ENTURE****C****APITAL****C****ORPORATION**                                     |
|       | **永豐創業投資股份有限公司** |
| ** ** | ** **                                                                                           |
| ** ** | ** **                                                                                           |
|       | By:                                                                                                  | /s/ Kuo Chi Yu |
|       | Name:                                                                                                | Kuo Chi Yu |
|       | Title:                                                                                               | Chairman |

 
| **NAME AND  ADDRESS**                                                                                                                                                                                                                                 | ** ** | **FIRST CLOSING  SHARES** | ** ** | **FIRST CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** | **SECOND  CLOSING SHARES** | ** ** | **SECOND CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------|------------|----------------------------------------------|------------|----------------------------|------------|-----------------------------------------------|------------|
| ** **                                                                                                                                                                                                                                            | ** ** | ** **                | ** ** | ** **                                   | ** ** | ** **                 | ** ** | ** **                                    | ** ** |
| **S****INOPAC****V****ENTURE****C****APITAL****C****ORPORATION**

**永豐創業投資股份有限公司**6F, No. 306, Section 2, Bade  RoadTaipei 10492, TaiwanAttn: Eric Chin |       | 792,000                   |       | NT $7,920,000                                |       | 1,848,000                  |       | NT $18,480,000                                |       |

 

[SIGNATURE PAGE TOFINANCING AGREEMENT]

 

----

 
|       | **PURCHASERS:**                                                                      |
|------------|--------------------------------------------------------------------------------------|
| ** ** | ** **                                                                           |
|       | **Futai  Investment Co., Ltd.**                                                      |
|       | **富鈦投資股份有限公司** |
| ** ** | ** **                                                                           |
| ** ** | ** **                                                                           |
|       | By:                                                                                  | /s/ Wei-hsu Tan |
|       | Name:                                                                                | Wei-hsu Tan |
|       | Title:                                                                               |   |

 
| **NAME AND  ADDRESS**                                                                                                                                                                                       | ** ** | **FIRST CLOSING  SHARES** | ** ** | **FIRST CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** | **SECOND  CLOSING SHARES** | ** ** | **SECOND CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------|------------|----------------------------------------------|------------|----------------------------|------------|-----------------------------------------------|------------|
| ** **                                                                                                                                                                                                  | ** ** | ** **                | ** ** | ** **                                   | ** ** | ** **                 | ** ** | ** **                                    | ** ** |
| **Futai Investment Co., Ltd.**

**富鈦投資股份有限公司**1F., No.321, Sec.  2, Shipai Road  Beitou Dist. 11267, Taipei  Taiwan  Attn: Connie Hsu |       | 792,000                   |       | NT $7,920,000                                |       | 1,848,000                  |       | NT $18,480,000                                |       |

 

[SIGNATURE PAGE TOFINANCING AGREEMENT]

 

----

 
|       | **PURCHASERS:**                              |
|------------|----------------------------------------------|
| ** ** | ** **                                   |
|       | **GLOBAL STRATEGIC INVESTMENT I****NC****.** |
| ** ** | ** **                                   |
| ** ** | ** **                                   |
|       | By:                                          | /s/ Shih-Chien Yang |
|       | Name:                                        | Shih-Chien Yang |
|       | Title:                                       | Chairman |

 
| **NAME AND  ADDRESS**                                                                                                          | ** ** | **FIRST CLOSING  SHARES** | ** ** | **FIRST CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** | **SECOND  CLOSING SHARES** | ** ** | **SECOND CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** |
|--------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------|------------|----------------------------------------------|------------|----------------------------|------------|-----------------------------------------------|------------|
| ** **                                                                                                                     | ** ** | ** **                | ** ** | ** **                                   | ** ** | ** **                 | ** ** | ** **                                    | ** ** |
| **GLOBAL STRATEGIC INVESTMENT I****NC****.**

9F, No. 65, Tun Hwa  South  Road, Sec. 2Taipei 106, TaiwanAttn: David Cheng |       | 792,000                   |       | NT $7,920,000                                |       | 1,848,000                  |       | NT $18,480,000                                |       |

 

[SIGNATURE PAGE TOFINANCING AGREEMENT]

 

----

 
|       | **PURCHASERS:**                                                                                                      |
|------------|----------------------------------------------------------------------------------------------------------------------|
| ** ** | ** **                                                                                                           |
|       | **FUBON  FINANCIAL HOLDING VENTURE CAPITAL CORP.**                                                                   |
| ** ** | **富邦金控創業投資股份有限公司** |
| ** ** | ** **                                                                                                           |
| ** ** | ** **                                                                                                           |
|       | By:                                                                                                                  | /s/ Chu Hsin Lee |
|       | Name:                                                                                                                | Chu Hsin Lee |
|       | Title:                                                                                                               | President |

 
| **NAME AND  ADDRESS**                                                                                                                                                                                                                                    | ** ** | **FIRST CLOSING  SHARES** | ** ** | **FIRST CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** | **SECOND  CLOSING SHARES** | ** ** | **SECOND CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------|------------|----------------------------------------------|------------|----------------------------|------------|-----------------------------------------------|------------|
| ** **                                                                                                                                                                                                                                               | ** ** | ** **                | ** ** | ** **                                   | ** ** | ** **                 | ** ** | ** **                                    | ** ** |
| **Fubon Financial Holding Venture Capital Corp.**

**富邦金控創業投資股份有限公司**8F, 108, Section 1, Tun Hwa  South RoadTaipei 10557, TaiwanAttn: Mei-Ann Liu |       | 792,000                   |       | NT $7,920,000                                |       | 1,848,000                  |       | NT $18,480,000                                |       |

 

[SIGNATURE PAGE TOFINANCING AGREEMENT]

 

----

 
|       | **PURCHASERS:**    |
|------------|--------------------|
| ** ** | ** **         |
|       | **CHENG HSU JEAN** |
| ** ** | ** **         |
| ** ** | ** **         |
|       | By:                | /s/ Cheng Hsu Jean |
|       | Name:              | Cheng Hsu Jean |
|       | Title:             |   |

 
| **NAME AND  ADDRESS**                                                              | ** ** | **FIRST CLOSING  SHARES** | ** ** | **FIRST CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** | **SECOND  CLOSING SHARES** | ** ** | **SECOND CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** |
|------------------------------------------------------------------------------------|------------|---------------------------|------------|----------------------------------------------|------------|----------------------------|------------|-----------------------------------------------|------------|
| ** **                                                                         | ** ** | ** **                | ** ** | ** **                                   | ** ** | ** **                 | ** ** | ** **                                    | ** ** |
| **Cheng Hsu  Jean**4F, No. 6, alley 33, Lane 361, Wu-hsin StreetTaipei 110, Taiwan |       | 792,000                   |       | NT $7,920,000                                |       | 1,848,000                  |       | NT $18,480,000                                |       |

 

[SIGNATURE PAGE TOFINANCING AGREEMENT]

 

----

 

**EXHIBIT A**

** **

**SCHEDULE OF PURCHASERS**

 
| **NAME AND  ADDRESS**                                                                                                                                                                                                                                      | ** ** | **FIRST CLOSING  SHARES** | ** ** | **FIRST CLOSING  AGGREGATE  PURCHASE PRICE** | ** ** | **SECOND  CLOSING SHARES** | ** ** | **SECOND CLOSING  AGGREGATE PURCHASE  PRICE** | ** ** |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------|------------|----------------------------------------------|------------|----------------------------|------------|----------------------------------------------------|------------|
| ** **                                                                                                                                                                                                                                                 | ** ** | ** **                | ** ** | ** **                                   | ** ** | ** **                 | ** ** | ** **                                         | ** ** |
| **OPTIMER PHARMACEUTICALS, INC.**10110 Sorrento Valley Rd.,  Suite CSan Diego, CA 92121Attn: John Prunty                                                                                                                                              |       | 11,880,000                |       | NT $118,800,000                              |       | 27,720,000                 |       | NT $277,200,000                                    |       |
| ** **                                                                                                                                                                                                                                                 |       |                      |       |                                         |       |                       |       |                                               |       |
| **HUEI HONG  INVESTMENT CO., LTD.**11F, No. 308, Section 2, Bade  RoadTaipei 10492, TaiwanAttn: Frank Chen                                                                                                                                       |       | 1,188,000                 |       | NT $11,880,000                               |       | 2,772,000                  |       | NT $27,720,000                                     |       |
| ** **                                                                                                                                                                                                                                                 |       |                      |       |                                         |       |                       |       |                                               |       |
| **UNIMED****I****NVESTMENT  INC.**

**合一生技投資股份有限公司**3F, No. 308, Section 2, Bade  RoadTaipei 10492, TaiwanAttn: Howard Lee                                   |       | 1,584,000                 |       | NT $15,840,000                               |       | 3,696,000                  |       | NT $36,960,000                                     |       |
| ** **                                                                                                                                                                                                                                                 |       |                      |       |                                         |       |                       |       |                                               |       |
| **E.SUN****V****ENTURE****C****APITAL****C****O.,****L****TD.**

**玉山創業投資股份有限公司******14F, No. 117, Section  3,Minsheng E. RoadTaipei 10546, TaiwanAttn: Mike Tsai |       | 950,400                   |       | NT $9,504,000                                |       | 2,217,600                  |       | NT $22,176,000                                     |       |
| ** **                                                                                                                                                                                                                                                 |       |                      |       |                                         |       |                       |       |                                               |       |
| **H****UNG****-M****EI****Y****EH**

葉鴻美****14F, No. 117, Section  3,Minsheng E. RoadTaipei 10546, TaiwanAttn: Mike Tsai                                                                                                         |       | 237,600                   |       | NT $2,376,000                                |       | 554,400                    |       | NT $5,544,000                                      |       |

 

----

 
| **S****INOPAC****V****ENTURE****C****APITAL****C****ORPORATION**

**永豐創業投資股份有限公司**6F, No. 306, Section 2, Bade  RoadTaipei 10492, TaiwanAttn: Eric Chin    |   | 792,000    |   | NT $7,920,000   |   | 1,848,000  |   | NT $18,480,000  |   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------|--------|-----------------|--------|------------|--------|-----------------|--------|
| ** **                                                                                                                                                                                                                                               |   |       |   |            |   |       |   |            |   |
| **Futai Investment Co., Ltd.**

**富鈦投資股份有限公司**1F., No.321, Sec.  2, Shipai Road  Beitou Dist. 11267, Taipei  Taiwan  Attn: Connie Hsu                                              |   | 792,000    |   | NT $7,920,000   |   | 1,848,000  |   | NT $18,480,000  |   |
| ** **                                                                                                                                                                                                                                               |   |       |   |            |   |       |   |            |   |
| **GLOBAL STRATEGIC INVESTMENT I****NC****.**

9F, No. 65, Tun Hwa  South  Road, Sec. 2Taipei 106, TaiwanAttn: David Cheng                                                                                                                           |   | 792,000    |   | NT $7,920,000   |   | 1,848,000  |   | NT $18,480,000  |   |
| ** **                                                                                                                                                                                                                                               |   |       |   |            |   |       |   |            |   |
| **FUBON FINANCIAL HOLDING VENTURE CAPITAL CORP.**

**富邦金控創業投資股份有限公司**8F, 108, Section 1, Tun Hwa  South RoadTaipei 10557, TaiwanAttn: Mei-Ann Liu |   | 792,000    |   | NT $7,920,000   |   | 1,848,000  |   | NT $18,480,000  |   |
| ** **                                                                                                                                                                                                                                               |   |       |   |            |   |       |   |            |   |
| **Cheng Hsu  Jean**4F, No. 6, alley 33, Lane 361, Wu-hsin StreetTaipei 110, Taiwan                                                                                                                                                                       |   | 792,000    |   | NT $7,920,000   |   | 1,848,000  |   | NT $18,480,000  |   |
| ** **                                                                                                                                                                                                                                               |   |       |   |            |   |       |   |            |   |
| **TOTAL:**                                                                                                                                                                                                                                               |   | 19,800,000 |   | NT $198,000,000 |   | 46,200,000 |   | NT $462,000,000 |   |

 

----

 

**EXHIBIT B**

 

**MILESTONES**

 

1.                                         Filing of an investigational new drugapplication (***“IND”***) or equivalent thereofwith the appropriate regulatory authority in Taiwan and the initiation of aPhase 2/3 trial for OPT-822/821.

 

2.             Filing of an IND with the U.S. Foodand Drug Administration for OPT-88.

 

----